Michael J Wong

US Patent:

6433138, Aug 13, 2002

Filed:

Nov 25, 1998

Appl. No.:

09/199865

Inventors:

Ann B. Zimrin - Marriottsville MD
Michael Wong - Derwood MD
Thomas Maciag - Freeport ME
Michael S. Pepper - Geneva, CH
Roberto Montesano - Geneva, CH

Assignee:

Maine Medical Center Research Institute - Scarborough ME

International Classification:

A61K 3817

US Classification:

530350, 514 12, 514 44, 536 235

Abstract:

This invention relates to therapeutic and diagnostic methods and compositions based on Jagged/Notch proteins and nucleic acids, and on the role of their signaling pathway in endothelial cell migration and/or differentiation. In addition, this invention provides a substantially purified Jagged protein, as well as a substantially purified nucleic acid molecule or segment thereof encoding Jagged protein, or a functionally equivalent derivative, or allelic or species variant thereof.

US Patent:

6825007, Nov 30, 2004

Filed:

Aug 6, 2002

Appl. No.:

10/213329

Inventors:

Ann B. Zimrin - Marriottsville MD
Thomas Maciag - Freeport ME
Michael S. Pepper - Geneva, CH
Roberto Montesano - Geneva, CH
Michael Wong - Derwood MD

Assignee:

Maine Medical Center Research Institute - Scarborough ME

International Classification:

C12P 2106

US Classification:

435 691, 435455, 4352523, 4353201

Abstract:

This invention relates to therapeutic and diagnostic methods and compositions based on Jagged/Notch proteins and nucleic acids, and on the role of their signaling pathway in endothelial cell migration and/or differentiation. In addition, this invention provides a substantially purified Jagged protein, as well as a substantially purified nucleic acid molecule or segment thereof encoding Jagged protein, or a functionally equivalent derivative, or allelic or species variant thereof.

US Patent:

D562718, Feb 26, 2008

Filed:

May 1, 2007

Appl. No.:

29/286290

Inventors:

Michael Wong - New York NY, US

International Classification:

1101

US Classification:

D11 40

US Patent:

8609635, Dec 17, 2013

Filed:

Mar 4, 2011

Appl. No.:

13/041082

Inventors:

Anilkumar Gopinadhan Nair - Edison NJ, US
Kartik M. Keertikar - East Windsor NJ, US
Seong Heon Kim - Livingston NJ, US
Joseph A. Kozlowski - Princeton NJ, US
Stuart Rosenblum - West Orange NJ, US
Oleg B. Selyutin - West Windsor NJ, US
Michael Wong - Somerset NJ, US
Wensheng Yu - Edison NJ, US
Qingbei Zeng - Edison NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/695
C07F 7/10

US Classification:

514 63, 544 60, 544 69, 546 14, 548110

Abstract:

The present invention relates to novel Fused Tricyclic Silyl Compounds of Formula (I):.

US Patent:

20060205797, Sep 14, 2006

Filed:

Jul 13, 2005

Appl. No.:

11/180863

Inventors:

Wensheng Yu - Edison NJ, US
Ling Tong - Warren NJ, US
Lei Chen - Roselle Park NJ, US
Joseph Kozlowski - Princeton NJ, US
Brian Lavey - New Providence NJ, US
Neng-Yang Shih - Warren NJ, US
Vincent Madison - Mountain Lakes NJ, US
Guowei Zhou - Livingston NJ, US
Peter Orth - New York NY, US
Zhuyan Guo - Scotch Plains NJ, US
Michael Wong - North Brunswick NJ, US
De-Yi Yang - Morris Plains NJ, US
Seong Kim - Livingston NJ, US
Bandarpalle Shankar - Branchburg NJ, US

International Classification:

A61K 31/425
A61K 31/4178
C07D 417/02
C07D 403/02

US Classification:

514373000, 514389000, 548311100, 548213000

Abstract:

This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF—combinations thereof.

US Patent:

20060276448, Dec 7, 2006

Filed:

Feb 14, 2006

Appl. No.:

11/353474

Inventors:

Qingbei Zeng - Edison NJ, US
De-Yi Yang - Morris Plains NJ, US
Stuart Rosenblum - West Orange NJ, US
Michael Wong - North Brunswick NJ, US
Gopinadhan Anilkumar - Edison NJ, US
Seong Kim - Livingston NJ, US
Wensheng Yu - Edison NJ, US
Joseph Kozlowski - Princeton NJ, US
Neng-Yang Shih - Warren NJ, US
Brian McGuinness - Plainsboro NJ, US
Doublas Hobbs - Yardley PA, US

International Classification:

A61K 31/5377
A61K 31/506
A61K 31/497
C07D 413/14
C07D 403/14

US Classification:

514210200, 514252110, 544357000, 514235500, 544295000, 544120000

Abstract:

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

US Patent:

20060276479, Dec 7, 2006

Filed:

Feb 14, 2006

Appl. No.:

11/353641

Inventors:

Seong Kim - Livingston NJ, US
Gopinadhan Anilkumar - Edison NJ, US
Michael Wong - North Brunswick NJ, US
Qingbei Zeng - Edison NJ, US
Stuart Rosenblum - West Orange NJ, US
Joseph Kozlowski - Princeton NJ, US
Yuefei Shao - Princeton NJ, US
Brian McGuinness - Plainsboro NJ, US
Douglas Hobbs - Yardley PA, US

International Classification:

A61K 31/497
C07D 413/14
C07D 403/14

US Classification:

514252120, 544357000

Abstract:

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

US Patent:

20060276480, Dec 7, 2006

Filed:

Feb 14, 2006

Appl. No.:

11/354328

Inventors:

Michael Wong - North Brunswick NJ, US
Youheng Shu - Blue Bell PA, US
Wensheng Yu - Edison NJ, US
Stuart Rosenblum - West Orange NJ, US
Joseph Kozlowski - Princeton NJ, US
Brian McGuinness - Plainsboro NJ, US
Yuefei Shao - Princeton NJ, US
Douglas Hobbs - Yardley PA, US

International Classification:

A61K 31/496
C07D 403/14

US Classification:

514253010, 544364000

Abstract:

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.